1255717-04-4

Basic information

• Product Name: methyl 2-(benzyloxycarbonylamino)-2-(oxetan-3-yl)acetate
• Synonyms: methyl 2-(benzyloxycarbonylamino)-2-(oxetan-3-yl)acetate
• CAS NO: 1255717-04-4
• Molecular Weight: 279.293
• Mol File: 1255717-04-4.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: methyl 2-(benzyloxycarbonylamino)-2-(oxetan-3-yl)acetate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 2-(benzyloxycarbonylamino)-2-(oxetan-3-yl)acetate(1255717-04-4)
• EPA Substance Registry System: methyl 2-(benzyloxycarbonylamino)-2-(oxetan-3-yl)acetate(1255717-04-4)

Safety Data

• Hazardous Substances Data: 1255717-04-4(Hazardous Substances Data)

Upstream product

• 13139-17-8 N-(Benzyloxycarbonyloxy)succinimide 
• 394653-40-8 methyl 2-amino-2-(oxetan-3-yl)acetate 
• 501-53-1 benzyl chloroformate 
• 394653-39-5 N-benzyloxycarbonyl-α,β-didehydro-(3-oxetanyl)glycine methyl ester 

Downstream Products

• 1213783-62-0 (S)-methyl 2-(benzyloxycarbonylamino)-2-(oxetan-3-yl)acetate 
• 1616889-73-6 C₁₃H₁₅NO₅ 
• 1213783-61-9 (R)-methyl 2-(benzyloxycarbonylamino)-2-(oxetan-3-yl)acetate 

Relevant articles and documents

Improving the metabolic stability of antifungal compounds based on a scaffold hopping strategy: Design, synthesis, and structure-activity relationship studies of dihydrooxazole derivatives

L-amino alcohol derivatives exhibited high antifungal activity, but the metabolic stability of human liver microsomes in vitro was poor, and the half-life of optimal compound 5 was less than 5 min. To improve the metabolic properties of the compounds, the scaffold hopping strategy was adopted and a series of antifungal compounds with a dihydrooxazole scaffold was designed and synthesized. Compounds A33-A38 substituted with 4-phenyl group on dihydrooxazole ring exhibited excellent antifungal activities against C. albicans, C. tropicalis and C. krusei, with MIC values in the range of 0.03–0.25 μg/mL. In addition, the metabolic stability of compounds A33 and A34 in human liver microsomes in vitro was improved significantly, with the half-life greater than 145 min and the half-life of 59.1 min, respectively. Moreover, pharmacokinetic studies in SD rats showed that A33 exhibited favourable pharmacokinetic properties, with a bioavailability of 77.69%, and half-life (intravenous administration) of 9.35 h, indicating that A33 is worthy of further study.

The discovery of potent nonstructural protein 5A (NS5A) inhibitors with a unique resistance profile - Part 2

In ongoing studies towards novel hepatitis C virus (HCV) therapeutics, inhibitors of nonstructural protein 5A (NS5A) were evaluated. Specifically, starting from previously reported lead compounds, peripheral substitution patterns of a series of biaryl-linked pyrrolidine NS5A replication complex inhibitors were probed and structure-activity relationships were elucidated. Using molecular modelling and a supercritical fluid chromatographic (SFC) technique, intramolecular H-bonding and peripheral functional group topology were evaluated as key determinants of activity and membrane permeability. The novel compounds exhibited retained potency as compared with the lead compounds, and also showed promising results against a panel of resistance viruses. Together, the results of the study take us a step closer towards understanding the potency of daclatasvir, a clinical candidate upon which the compounds were based, and to designing improved analogues as second-generation antiviral agents targeting NS5A. Refining the resistance: An investigation into the anti-hepatitis C virus (HCV) replicon activity of a series of biaryl-linked prolinamide NS5A inhibitors explored intramolecular H-bonding and peripheral functional group topology as key determinants of activity and membrane permeability. Studies of several peripheral group molecular designs resulted in compounds with improved aqueous solubility and a unique resistance profile.